# A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

> **NCT01005901** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1324 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Glycopyrronium bromide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01005901
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 1324 (ACTUAL)
- **Last updated:** 2012-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01005901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01005901, "A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01005901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*